Premiums for Medicare Part D, which covers prescription drugs, could increase next year. This rise relates to the termination of subsidies provided to insurers. The Trump administration decided to end these subsidies, which previously helped maintain low costs for Medicare drug coverage.
Under the Inflation Reduction Act of 2022, out-of-pocket drug expenses for Medicare patients were capped at $2,000 starting in 2025. This change affected how insurers paid for medications. Patients benefited from paying less at pharmacies, but insurers had to cover more of the costs.
Initially, it was unclear to insurers how to adjust their spending and premium settings. To support a smoother transition, the Biden administration initiated temporary subsidies through a demonstration project. These subsidies were intended to last until 2027 but are ending a year earlier.
Dr. Mehmet Oz, overseeing the Centers for Medicare and Medicaid, announced this change on the social media platform X. He criticized the subsidies, stating that the Biden administration allocated billions of taxpayer dollars to insurance companies. The Government Accountability Office reported that the subsidies would have cost $9.8 billion in 2025 and 2026.
According to Juliette Cubanski from KFF, while some Medicare enrollees might see minimal increases in premiums, others could face higher costs. She highlighted that subsidies this year reduced the average drug plan premium by $16. Without this support, premiums would have been significantly higher.
Further details from the Centers for Medicare and Medicaid Services are awaited to understand the exact financial impact on seniors more clearly.
Stacie Dusetzina from Vanderbilt University expressed concern about the early termination of the subsidies. She noted that standalone Medicare drug plans benefitted most from these subsidies while Medicare Advantage plans usually maintained lower premiums. Removal of subsidies primarily affects traditional Medicare plan enrollees.
The Heritage Foundation proposed shifting more people into Medicare Advantage as part of a future strategy. Traditional Medicare could become costlier, encouraging a switch to Medicare Advantage plans. Though these plans may offer lower premiums, they require careful consideration of long-term healthcare needs due to potential provider network limitations.